Experimental triple therapy takes on Hard-to-Treat Head-Neck cancer
NCT ID NCT05838729
First seen Jun 25, 2026 · Last updated Jun 26, 2026 · Updated 2 times
Summary
This early-phase trial is testing a new drug called RiMO-301, given as an injection directly into the tumor, along with radiation therapy and an immunotherapy drug (a PD-1 inhibitor). The goal is to see if this combination is safe and can shrink tumors in people with advanced head-neck cancer that cannot be removed by surgery. The study plans to enroll 16 participants.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- RiMO-301 (a drug injected into the tumor) combined with radiation therapy and a PD-1 inhibitor (pembrolizumab or nivolumab)
- What this could lead to
- If successful, this could point toward a new treatment option for people with advanced head-neck cancer that has not responded to other therapies.
- What could go wrong
- This is a very early, small trial with only 16 participants, so results may not apply to everyone. The combination therapy may cause serious side effects or fail to shrink tumors.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
University of Illinois at Chicago
RECRUITINGChicago, Illinois, 60612, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Digital peer support: a new weapon against cancer treatment anxiety?
- Can targeted radiation boost Immunotherapy's power against head and neck cancer?
- Can a new drug combo revive Immunotherapy's power against resistant tumors?
- Could a simple mouthwash protect cancer patients from Radiation's painful side effects?
- Can a scan tell who needs more surgery after head and neck cancer?
- Can a new drug outperform standard care for head and neck cancer?